Concord Drugs approves FY26 financials, sets September 30 AGM date

ScanX News Concord Drugs approves FY26 financials, sets September 30 AGM date 1 min read | Published on 08 Sept 2026, 12:48 AM | Updated on 08 Sept 2026, 12:59 AM Reviewed by Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. Concord Drugs board approved the company's audited standalone and consolidated financial statements for FY26 during a meeting held on September 7, 2026. The directors also approved the notice for the 31st Annual General Meeting (AGM), scheduled to take place via video conferencing on September 30, 2026. The board set the record date for remote e-voting eligibility as September 23, 2026. The register of members and share transfer books will remain closed from September 24 to September 30, 2026, both days inclusive. Governance and Appointments The board proposed the re-appointment of S. Nagi Reddy, Chairman and Managing Director, who retires by rotation at the ensuing AGM. Reddy holds 30,60,536 equity shares in the company and has approximately 28 years of experience in the pharmaceutical industry. Two independent directors were also recommended for re-appointment for second terms of five consecutive years: S. Nagavenkata Hareesh Kumar Solleti, subject to member approval Sumeela Kasu, with a term commencing June 1, 2027, to May 31, 2032 Auditor and Transaction Approvals Based on the Audit Committee's recommendation, the board approved the re-appointment of Pundarikashyam and Associates as statutory auditors for five consecutive years. The proposed remuneration is ₹4,00,000 per annum, plus applicable taxes and reimbursement of reasonable out-of-pocket expenses. The board also sought member approval for material related-party transactions proposed for FY27, stating these would be undertaken in the ordinary course of business on an arm's-length basis. Additionally, the remuneration of KJU & Associates, appointed as cost auditors for FY27, requires ratification by members. What the Numbers Show The filing focuses on procedural governance rather than operational performance metrics. With no revenue, profit, or order inflow data disclosed in this specific board outcome notice, the primary signal is continuity in leadership and audit oversight, ensuring stability in corporate governance for the upcoming fiscal year. Historical Stock Returns for Concord Drugs 1 Day 5 Days 1 Month 6 Months 1 Year 5 Years - 1. 39 % - 1. 76 % + 11. 89 % + 10. 68 % + 24. 53 % 0.0% How will the re-appointment of Chairman S. Nagi Reddy influence Concord Drugs' strategic direction and market positioning in FY27? fuzz it What specific operational or financial metrics are investors anticipating in the upcoming standalone and consolidated financial statements for FY26? fuzz it Could the approval of material related-party transactions for FY27 signal any changes in supply chain dependencies or internal cost structures? fuzz it ScanX News Concord Drugs approves FY26 financials, sets September 30 AGM date 0 min read | Published on 07 Sept 2026, 09:16 PM | Updated on 07 Sept 2026, 09:50 PM Reviewed by Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. Concord Drugs has fixed Wednesday, September 23, 2026, as the cut-off date for determining shareholders eligible to vote at its 31st Annual General Meeting. The meeting is scheduled for September 30, 2026. The company notified BSE Limited on September 7, 2026, pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice included the submission of the Annual Report for FY26. Meeting Details The AGM will be held on Wednesday, September 30, 2026, starting at 9:30 am. It will be conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM), in compliance with circulars from the Ministry of Corporate Affairs and SEBI. Shareholder Eligibility and Book Closure The Register of Members, Share Transfer Books, and other company books will remain closed from September 24, 2026, to September 30, 2026, inclusive. This closure is mandated under Section 91 of the Companies Act, 2013, and Regulation 42 of the SEBI (LODR) Regulations, 2015. Shareholders on record as of September 23, 2026, will be eligible to cast electronic votes. The Annual Report is available on the company's website. Historical Stock Returns for Concord Drugs 1 Day 5 Days 1 Month 6 Months 1 Year 5 Years - 1. 39 % - 1. 76 % + 11. 89 % + 10. 68 % + 24. 53 % 0.0% What key financial metrics or strategic initiatives from FY26 are likely to be highlighted in the Annual Report submitted to BSE? fuzz it How might the resolution of any special business items at the AGM impact Concord Drugs' future dividend policy or capital allocation strategy? fuzz it Are there any anticipated changes to the board composition or management structure that shareholders should prepare for during the vote? fuzz it view all